Mirum Pharmaceuticals clinical trials we track

Check company identity source

Phase 3 9 trials

TrialDrugs studiedStatusPrimary completion
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)NCT07200908Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mgRecruiting2027-06-30Estimated
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)NCT07298330Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mgActive not recruiting2026-08Estimated
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)NCT06553768MaralixibatActive not recruiting2026-07-29Actual
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)NCT04185363MaralixibatCompleted2025-04-23Actual
Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)NCT04270682Blinded CDCA 250 mg TID, CDCA Weight-Based Dose TID, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TIDCompleted2023-07-13Actual
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)NCT03905330MaralixibatCompleted2022-09-01Actual
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid SynthesisNCT01438411Cholic AcidCompleted2016-07Actual
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid SynthesisNCT01115582Cholic acidCompleted2010-08Actual
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidNCT00007020Cholic AcidsCompleted2009-12Actual

Phase 2 / 3 2 trials

Phase 2 8 trials

TrialDrugs studiedStatusPrimary completion
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)NCT07209462High dose of MRM-3379, Low dose of MRM-3379, Low dose of MRM-3379 Open-Label, Middle Dose of MRM-3379Recruiting2027-10Estimated
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisNCT05050136VolixibatActive not recruiting2027-01Estimated
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)NCT04663308VolixibatActive not recruiting2026-02-20Actual
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).NCT04729751MaralixibatCompleted2024-12-17Actual
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyNCT04168385MaralixibatCompleted2024-09-04Actual
Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiNCT04524390MaralixibatCompleted2023-11-07Actual
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic CholestasisNCT02057718LUM001 (Maralixibat)Completed2020-05-08Actual
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)NCT04718961VolixibatTerminated2022-12-07Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 260 participants (planned). After: 333 participants (actual).

Primary completion date changed

Before: Apr 2027. After: Jan 2027.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs) during the study. After: Measure: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score.

Actual enrollment decreased by 6 participants

Before: 90 participants (actual). After: 84 participants (actual).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency of treatment-emergent adverse events [TEAEs]. After: Measure: Frequency of Treatment-emergent Adverse Events [TEAEs].

Check registry source